Page last updated: 2024-09-02

carboxyamido-triazole and paclitaxel

carboxyamido-triazole has been researched along with paclitaxel in 3 studies

Compound Research Comparison

Studies
(carboxyamido-triazole)
Trials
(carboxyamido-triazole)
Recent Studies (post-2010)
(carboxyamido-triazole)
Studies
(paclitaxel)
Trials
(paclitaxel)
Recent Studies (post-2010) (paclitaxel)
105152231,8745,72915,395

Protein Interaction Comparison

ProteinTaxonomycarboxyamido-triazole (IC50)paclitaxel (IC50)
Integrin beta-3Homo sapiens (human)0.034
Integrin alpha-V Homo sapiens (human)0.034
ATP-dependent translocase ABCB1Homo sapiens (human)2.598
Botulinum neurotoxin type A Clostridium botulinum5.2
UDP-glucuronosyltransferase 2B7Homo sapiens (human)4.9
UDP-glucuronosyltransferase 1-6Homo sapiens (human)4.9
Substance-K receptorHomo sapiens (human)6.125
UDP-glucuronosyltransferase 1A1 Homo sapiens (human)4.9
UDP-glucuronosyltransferase 1A4Homo sapiens (human)4.9
UDP-glucuronosyltransferase 2B10 Homo sapiens (human)4.9
Delta-type opioid receptorHomo sapiens (human)4.202
Tyrosine-protein kinase MerHomo sapiens (human)4.9
Tubulin beta-3 chainHomo sapiens (human)0.0082
Beta-tubulin Leishmania donovani1
Nucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)7.9433
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)0.26
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)0.28

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (33.33)18.2507
2000's2 (66.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, PS1
Bauer, KS; Bostick-Bruton, F; Figg, WD; Fuse, E; Goldspiel, B; Kohn, EC; Kulpa, V; Liotta, LA; Minasian, L; Noone, M; Pluda, J; Reed, E; Sarosy, GA; Tompkins, A1
Azad, N; Figg, WD; Gardner, E; Graves, C; Imamura, CK; Kohn, EC; Kotz, H; Minasian, L; Perroy, A; Raggio, M; Sarosy, GA1

Trials

2 trial(s) available for carboxyamido-triazole and paclitaxel

ArticleYear
A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:6

    Topics: Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Nude; Middle Aged; Neoplasms; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Recurrence; Time Factors; Treatment Outcome; Triazoles; Tumor Cells, Cultured

2001
A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors.
    Cancer biology & therapy, 2009, Volume: 8, Issue:19

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Treatment Outcome; Triazoles; Young Adult

2009

Other Studies

1 other study(ies) available for carboxyamido-triazole and paclitaxel

ArticleYear
Biotechnology transfer at the National Institutes of Health.
    Quality assurance (San Diego, Calif.), 1993, Volume: 2, Issue:4

    Topics: Aminoimidazole Carboxamide; Antineoplastic Agents; Biotechnology; Ethics, Medical; Humans; Industry; National Institutes of Health (U.S.); Paclitaxel; Proteins; Research; Research Support as Topic; Technology Transfer; Tissue Inhibitor of Metalloproteinase-2; Triazoles; United States

1993